![3-(hydroxyimino)-[2,3'-biindolinylidene]-2'-one](https://www.chemshuttle.com/media/catalog/product/cache/31dbf0bffbfa69a5826a72cec9a446de/1/9/194273_1.jpg)
YKL-5-124
$400.00
CAS No.: 1957203-01-8
Catalog No.: 193686
Purity: 95%
MF: C28H33N7O3
MW: 515.618
Storage: 2-8 degree Celsius
SMILES: C(C=C)(=O)NC1=CC=C(C(=O)NC=2C3=C(NN2)C(N(C3)C(=O)N[C@H](CN(C)C)C3=CC=CC=C3)(C)C)C=C1
Catalog No.: 193686
Purity: 95%
MF: C28H33N7O3
MW: 515.618
Storage: 2-8 degree Celsius
SMILES: C(C=C)(=O)NC1=CC=C(C(=O)NC=2C3=C(NN2)C(N(C3)C(=O)N[C@H](CN(C)C)C3=CC=CC=C3)(C)C)C=C1
YKL-5-124; (S)-3-(4-acrylamidobenzamido)-N-(2-(dimethylamino)-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide; CAS No.: 1957203-01-8; YKL-5-124. PROPERTIES: YKL-5-124 is a crystalline compound with the molecular formula C19H20F3N5O3. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 421.39 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms that enhance binding affinity and metabolic resistance. Its logP value around 2.5 indicates a balance between solubility and membrane permeability. APPLICATIONS: YKL-5-124 functions as a selective inhibitor of the protein kinase D (PKD) family, investigated for the treatment of various cancers including leukemia and solid tumors. In preclinical research, it is used to study PKD's role in cancer cell survival and proliferation and to develop novel therapeutic approaches. The compound is employed in combination studies with other targeted therapies to enhance antitumor efficacy. Additionally, it serves as a research tool in cell signaling to investigate PKD-mediated pathways and in drug discovery to explore structure-activity relationships of PKD inhibitors. According to "Protein Kinase D in Cancer: From Biology to Therapy," YKL-5-124 provides a promising approach to targeting PKD in cancer treatment.
Reviews
Write Your Own Review